Open Access<p>Patient Reported Ease-of-Use with a Disposable Autoinjector in Individuals with Migraine</p>
Author(s) -
Jennifer Mead,
Ryan Dammerman,
Soeren Rasmussen
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s248584
Subject(s) - medicine , migraine , headaches , calcitonin gene related peptide , confidence interval , likert scale , session (web analytics) , usability , family medicine , physical therapy , surgery , receptor , statistics , mathematics , neuropeptide , world wide web , computer science , human–computer interaction
Erenumab-aooe (erenumab, Aimovig ® )-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of countries. The approved monthly dosage of erenumab (70 and/or 140 mg, depending on the country) is available as a single, prefilled autoinjector for subcutaneous administration in most countries where it is approved. This study evaluated the patient-reported ease-of-use, ability to learn self-injection, confidence in performing a simulated self-injection, and ergonomics of a prefilled autoinjector device for erenumab (SureClick ® autoinjector) in individuals in the US with migraine.